Strides Shasun receives tentative nod from USFDA for HIV drug Efavirenz

Posted on:27 May 2016 14:36:06

Strides Shasun receives tentative nod from USFDA for HIV drug Efavirenz
27 May 2016 Current Affairs GK: Strides Shasun has announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for Efavirenz tablets USP, 600 mg on 26 May 2016.

The final approval will be received after patent expiry in August 2018. The company will manufacture the product at its oral dosage facility in Bengaluru.

About Efavirenz : Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI).It is used as part of Highly Active Antiretroviral Therapy (HAART) for the treatment of a Human Immunodeficiency Virus (HIV) type 1. It is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to reduce the risk of HIV infection in people exposed to a significant risk. It was discovered at Merck Research Laboratories.It is on the WHO Model List of Essential Medicines, the most important medication needed in a basic health system.

Strides Shasun : Strides Arcolab is an Indian pharmaceutical company, headquartered at Bangalore in southern India.The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals.The company has 15 manufacturing sites in six countries and marketing presence in 50 countries.The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.

Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab.Arun Kumar is the founder and Group CEO, and has been on the Board as Managing Director since its inception.

Gk Current Affairs April 2017

27 APRIL
NEWS
26 APRIL
NEWS
25 APRIL
NEWS
24 APRIL
NEWS

Gk Current Affairs March 2017

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS

Gk Current Affairs February 2017

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
25 FEBRUARY
NEWS
24 FEBRUARY
NEWS




Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.